These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32584835)

  • 1. End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia.
    Hoque S; Chen BJ; Schoen MW; Carson KR; Keller J; Witherspoon BJ; Knopf KB; Yang YT; Schooley B; Nabhan C; Sartor O; Yarnold PR; Ray P; Bobolts L; Hrushesky WJ; Dickson M; Bennett CL
    PLoS One; 2020; 15(6):e0234541. PubMed ID: 32584835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
    J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. End of an era for erythropoiesis-stimulating agents in oncology.
    Schoen MW; Hoque S; Witherspoon BJ; Schooley B; Sartor O; Yang YT; Yarnold PR; Knopf KB; Hrushesky WJM; Dickson M; Chen BJ; Nabhan C; Bennett CL
    Int J Cancer; 2020 May; 146(10):2829-2835. PubMed ID: 32037527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in Erythropoiesis-stimulating agent use and blood transfusions for chemotherapy-induced anemia throughout FDA's risk evaluation and mitigation strategy lifecycle.
    Vega A; Zhang R; Wong HL; Wernecke M; Alexander M; Feng Y; Lo AC; Lufkin B; Ryan Q; Izem R; MaCurdy TE; Kelman JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2021 May; 30(5):626-635. PubMed ID: 33534188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron.
    Henry DH; Dahl NV; Auerbach MA
    Am J Hematol; 2012 Mar; 87(3):308-10. PubMed ID: 22262486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002-2008.
    Tarlov E; Stroupe KT; Lee TA; Weichle TW; Zhang QL; Michaelis LC; Ozer H; Browning MM; Hynes DM
    Support Care Cancer; 2012 Aug; 20(8):1649-57. PubMed ID: 21935718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk evaluation mitigation strategy: impact of application of the Food and Drug Adminstration's strategy on use of erythropoiesis-stimulating agents and transfusion in patients with chemotherapy-induced anaemia.
    Hollingsworth K; Romney MC; Crawford A; McAna J
    J Clin Pharm Ther; 2015 Jun; 40(3):299-303. PubMed ID: 25893427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor progression associated with erythropoiesis-stimulating agents.
    Newland AM; Black CD
    Ann Pharmacother; 2008 Dec; 42(12):1865-70. PubMed ID: 19017828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.
    Gawade PL; Berlin JA; Henry DH; Tomita D; Brooks BD; Franklin J; Bradbury BD; Critchlow CW
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1357-1366. PubMed ID: 28809079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.
    Luo W; Nordstrom BL; Fraeman K; Nordyke R; Ranganathan G; Linz HE; Winterkorn A; Stokes M; Ross SD; Knopf K
    Clin Ther; 2008 Dec; 30(12):2423-35. PubMed ID: 19167601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update.
    Rizzo JD; Somerfield MR; Hagerty KL; Seidenfeld J; Bohlius J; Bennett CL; Cella DF; Djulbegovic B; Goode MJ; Jakubowski AA; Rarick MU; Regan DH; Lichtin AE; ;
    J Clin Oncol; 2008 Jan; 26(1):132-49. PubMed ID: 17954713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
    Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
    Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of erythropoiesis-stimulating agent prescribing at an Asian cancer center, after release of safety advisories.
    Chan Q; Chan A
    J Oncol Pharm Pract; 2011 Dec; 17(4):350-9. PubMed ID: 20659968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
    Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of the Risk Evaluation Mitigation Strategy for Erythropoiesis-Stimulating Agents on Their Use and the Incidence of Stroke in Medicare Subjects with Chemotherapy-Induced Anemia with Lung and/or Breast Cancers.
    Hollingsworth K; Romney MC; Crawford A; McAna J
    Popul Health Manag; 2016 Feb; 19(1):63-9. PubMed ID: 26102512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update.
    Rizzo JD; Somerfield MR; Hagerty KL; Seidenfeld J; Bohlius J; Bennett CL; Cella DF; Djulbegovic B; Goode MJ; Jakubowski AA; Rarick MU; Regan DH; Lichtin AE
    Blood; 2008 Jan; 111(1):25-41. PubMed ID: 17954703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in patients with cancer: the shift after United States Food and Drug Administration policy changes.
    Stroupe KT; Tarlov E; Lee TA; Weichle TW; Zhang QL; Michaelis LC; Ozer H; Durazo-Arvizu R; Browning MM; Hynes DM
    Pharmacotherapy; 2012 Nov; 32(11):988-97. PubMed ID: 23108695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia.
    Noxon V; Knopf KB; Norris LB; Chen B; Yang YT; Qureshi ZP; Hrushesky W; Lebby AA; Schooley B; Hikmet N; Dickson M; Thamer M; Cotter D; Yarnold PR; Bennett CL
    J Oncol Pract; 2017 Jun; 13(6):e562-e573. PubMed ID: 28504901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.
    Ross SD; Allen IE; Henry DH; Seaman C; Sercus B; Goodnough LT
    Clin Ther; 2006 Jun; 28(6):801-31. PubMed ID: 16860166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synchronization of administrations of chemotherapy and erythropoiesis-stimulating agents and frequency of associated healthcare visits.
    Hill JW; Shreay S; McGarvey N; De AP; Hess GP; Corey-Lisle PK
    Support Care Cancer; 2013 Nov; 21(11):2957-65. PubMed ID: 23756616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.